Tumor Mutational Burden • MSi-H Biomarker • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MGMT (6-O-methylguanine-DNA methyltransferase) • CCNE1 (Cyclin E1) • KMT2D (Lysine Methyltransferase 2D) • RNF43 (Ring Finger Protein 43) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • MSH3 (MutS Homolog 3) • GNAS (GNAS Complex Locus) • RSPO3 (R-Spondin 3) • CA 19-9 (Cancer antigen 19-9)
|
TP53 mutation • KRAS mutation • TMB-H • MSI-H/dMMR • HER-2 overexpression • PTEN mutation • MET overexpression • KRAS wild-type • RAS wild-type • MET expression • CCNE1 overexpression • RNF43 mutation • MGMT underexpression • NTRK expression
|
Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • leucovorin calcium